Is chemoradiation effective or harmful for stage VI gastric cancer patients?

Oncology Reports

Volumn 13, Issue 5, 2005, Pages 865-870

  Saikawa, Yoshiro ^a   Kubota, Tetsuro ^a   Takahashi, Tsunehiro ^a   Akatsu, Yukako ^a   Nakamura, Rieko ^a   Yoshida, Masashi ^a   Shigematsu, Naoyuki ^a   Otani, Yoshihide ^a   Kumai, Koichiro ^a   Hibi, Toshifumi ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cisplatin; Gastric cancer; Pre operative chemoradiation; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; QUALITY OF LIFE; RADIOTHERAPY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; QUALITY OF LIFE; RADIOTHERAPY; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 18544372370     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.5.865     Document Type: Article

References (24)

1. Hundahl SA, Phillips JL and Menck HR: The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 88: 921-932, 2000. (Pubitemid 30091113)
2. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F and Sullinger J: Patterns of failure following curative resection of gastric cancer. Int J Radiat Oncol Biol Phys 191: 1357-1362, 1990.
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stermmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
4. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Herper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M and Hickish T: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 80: 269-272, 1999. (Pubitemid 29210117)
5. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B and Wils JA: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Trace Cancer Cooperative Group. J Clin Oncol 18: 2648-2657, 2000. (Pubitemid 30465650)
6. Ravaud A, Borner M, Schellens JH, Geoffrois L, Schoffski BP, Kroon K, Hanauske AR and Fumoleau P; EORTC-ECSG: UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial. Eur J Cancer 37:1642-1647, 2001. (Pubitemid 32778610)
7. Garcia AA, Leichman CG, Lenz HJ, Baranda J, Lujan R, Casagrande Y and Leichman L: Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach. Jpn J Clin Oncol 31: 275-278,2001. (Pubitemid 32743254)
8. Harris BE, Song R, Soong ST and Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
9. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi VI, Kalo T, Yonekura K and Fukushima VI: Development ol'a novel form of an oral 5-fluorouracil derivatives (S-l) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
10. Shirasaka K, Shimamoto Y and Fukushima VI: Inhibition by oxanic acid of gastrointestinal toxicity of 5-fluorourail without loss of its antitumor activity in rats. Cancer Res 53:4004-4009, 1993. (Pubitemid 23267702)
11. Sugimachi K, Machara Y, Ilorikoshi N. Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivatives for advanced and recurrent gastroinlesiinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 57: 202-210, 1999. (Pubitemid 29481693)
12. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimklinc anticancer drug S-I (I M tegafur-0.4M gimestat-1M olastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
13. Chung YS, Yamashila Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Macda K, Sawada T, Kalo Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80: 1-7, 1997. (Pubitemid 27270913)
14. Shirasaka T, Yamamitsu S, Tsuji A and Taguchi T: Conceptual changes in cancer chemotherapy: From an oral fluoropyrimidinc prodrug, UFT, to a novel oral fluoropyrimidinc prodrug. S-1, and low-dose FP therapy in Japan. Invest New Drugs 18: 315-329, 2000.
15. Iwahashi M, Nakamori M, Tani M, Yainaue H, Sakaguchi S, Nakamura M, Ueda K, Ichiro M, Nishino E and Tanimura H: Complete response of highly advanced gastric cancer with peritoneal dissemination after new combined chemotherapy of S-1 and low dose cisplatin: Report of a case. Oncology 61: 16-22, 2001. (Pubitemid 32727583)
16. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA and Mansfield PF: A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 8: 519-524, 2001. (Pubitemid 32642608)
17. Ajani JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Raijman I, Swisher S, Martin FD and Roth JA: A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92: 279-286, 2001. (Pubitemid 32664433)
18. Arcangeli G, Saracino B, Arcangeli G, Angelini F, Marchetti P and Tirindelli Danesi D: Postoperative adjuvant chemoradiation in completely resected locally advanced gastric cancer. Int J Radial Oncol Biol Phys 54: 1069-1075, 2002. (Pubitemid 35292618)
19. Xiong HQ, Gunderson LL, Yao J and Ajani JA: Chemoradiation for resectable gastric cancer. Lancet Oncol 4: 498-505, 2003. (Pubitemid 37009959)
20. Constantinou VI, Tsai J Y and Safran H: Paclitaxel and concurrent radiation in upper gastrointestinal cancers. Cancer Invest 21: 887-896, 2003. (Pubitemid 38055986)
21. Saikawa Y, Akasaka Y, Kanai T, Otani Y, Kumai K, Kubota T and Kitajima M: Preoperative combination chemotherapy with S-1 and low close cisplatin against highly advanced gastric cancer. Oncol Rep 10: 381-386.2003.
22. Japanese Research Society for Gastric Cancer: Japanese classification of gastric carcinoma. 16th edition. Kanahara, Tokyo, Japan, 2001.
23. Official reference of CTC version 2.0: Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS 1998.
24. Roth AD, Allai AS, Brundler MA, de Peyer R, Mermillod B, Morel P and Huber O: Neoadjuvant chemoradiotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol 14: 110-115, 2003. (Pubitemid 36150268)